Full clinical recovery after topical acyclovir treatment of Epstein-Barr virus associated cutaneous B-cell lymphoma in patient with mycosis fungoides.
Primary cutaneous T- and B-cell lymphomas are a heterogeneous group of diseases with varied clinical presentations and prognosis. The use of new molecular, histological, and clinical criteria has improved their recognition. Cutaneous B-cell and T-cell lymphomas are seldom found together in the same patient. Here we report a rare case of mycosis fungoides variant of a cutaneous T-cell lymphoma (CTCL) which later developed Epstein-Barr virus (EBV) associated cutaneous B-cell lymphoproliferative disorder. The patient initially presented with generalized erythroderma, extensive plaques, and axillary lymphadenopathy. Histopathology and immunophenotyping of her tumor from the right breast nodule revealed a T-cell lymphoma consistent with mycosis fungoides. She was initially treated with pentostatin, followed by topical mechlorethamine and topical steroids. After progression of her mycosis fungoides with worsening diffuse skin lesions on this regimen, her treatments were changed to oral bexarotene with an initial partial response followed by stable disease. Three years from her initial presentation, she developed ulcerated cauliflower-like nodules on her forehead. Biopsy of these lesions revealed EBV-positive large- and medium-sized pleomorphic B-cells consistent with EBV-driven B-cell lymphoproliferative disorder. She was treated with topical acyclovir cream on the involved skin areas while continuing with oral bexarotene for mycosis fungoides. Skin lesions gradually diminished and totally disappeared after four weeks of topical acyclovir treatment. Bexarotene treatment was continued for another year until the mycosis fungoides progressed and became wide spread causing her death four and a half years after the initial diagnosis. The coexistence of two cutaneous non-Hodgkin lymphomas of different lineage in the same patient and the complete clinical response of EBV-related B-cell cutaneous component to topical acyclovir makes this rare case particularly interesting.
Copur
M Sitki
MS
Saint Francis Cancer Center, 2116 W Faidley Ave, Grand Island, NE 68802-9804, USA. mcopur@sfmc-gi.org
Deshpande
Anita
A
Mleczko
Kris
K
Norvell
Max
M
Hrnicek
Gordon J
GJ
Woodward
Suzette
S
Frankforter
Scott
S
Mandolfo
Natalie
N
Fu
Kai
K
Chan
Wing C
WC
D000212:Acyclovir / Q000627:therapeutic use*; D000287:Administration, Topical; D000998:Antiviral Agents / Q000627:therapeutic use*; D020031:Epstein-Barr Virus Infections / Q000150:complications / Q000188:drug therapy*; D005260:Female; D004854:Herpesvirus 4, Human / Q000302:isolation & purification; D006801:Humans; D016393:Lymphoma, B-Cell / Q000150:complications / Q000188:drug therapy* / Q000821:virology; D008875:Middle Aged; D009182:Mycosis Fungoides / Q000150:complications; D012878:Skin Neoplasms / Q000150:complications
D000998:Antiviral Agents; D000212:Acyclovir